SAN DIEGO, May 20, 2024 – Meet selectION’s management team for an update on selectION’s best-in-class ion channel blockers and the status of the clinical work in atopic dermatitis and psoriasis.
Site Search
Recent News
- selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of- Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease
- Congratulations to our Scientific Advisor, Dr. Fred Ramsdell, for receiving the 2025 Nobel Prize in Physiology.
- Meet selectION, Inc. at BIO International Convention in Boston,MA, on June 16th-19th, 2025